BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » COVID-19 Vaccine: IntelliStem Technologies Announces Successful Development of Peptide-Based Vaccine Against COVID-19
Intellistem

COVID-19 Vaccine: IntelliStem Technologies Announces Successful Development of Peptide-Based Vaccine Against COVID-19

April 6, 2020 By Cade Hildreth (CEO)

TORONTO, ON – April 6th, 2020—INTELLiSTEM Technologies Inc, a biotechnology company pioneering cellular vaccines and peptide therapeutics, announced the successful development of a peptide-based vaccine (IPT-001) intended for human use against COVID-19.

IPT-001 is a peptide-based vaccine developed using the novel coronavirus COVID-19. It was engineered using INTELLiPEPTIDOME™ Platform to target both the Spike (S) and Nucleocapsid (N) proteins.

“We have been validating INTELLiPEPTIDOME™ over the last 2 years starting with Ebola and Leishmania vaccines and moving to oncology. INTELLiPEPTIDOME™ is precisely developed to identify vaccine subunits against a target like COVID-19 in a fast, reliable and less expensive way” said Dr. Riam Shammaa, MD, Founder and CEO of INTELLiSTEM Technologies.

INTELLiSTEM takes a different direction on vaccine

“Our approach is to trigger both strong cellular and humoral responses leading to not only a therapeutic effect but also long-term protection (5-8 years) from COVID-19. The vaccine is also less expensive and faster to develop.” Said Dr. Shammaa.

“The power of the platform is that it can quickly be adapted to other pandemics and diseases, all we need is the proteins of the disease and within 5 weeks we can deliver a vaccine” said Dr. Shammaa.

“We are now in the process of IND submission, and final stages of preparing our Phase I clinical trial. We anticipate starting our Phase I trial as early as September 2020,” said Shammaa.

About IPT-001

IPT-001 is peptide vaccine against the Spike (S) and Nucleocapsid (N) proteins of COVID-19, which was developed by INTELLiSTEM using the INTELLiPEPTIDOME™ platform. The technology relies on our proprietary IntelliCells™ to identify peptides that will mount both cellular and humoral responses against the virus leading not only to a therapeutic effect against the virus, but also long-term protection.

About INTELLiPEPTIDOME™:

INTELLiPEPTIDOME™ platform allows for systematic analysis of peptides selected by our genetically engineered stem cells, IntelliCells™ for triggering efficient and specific immune responses. INTELLiPEPTIDOME™ profiles (Iding) the immunopeptidome of established pathogen for the development of universal vaccines designed to stimulate a patient’s immune response to the antigen-derived epitopes. It can also be used the discovery of novel epitopes for monoclonal antibody development as well.

About INTELLiSTEM TECHNOLOGIES:

INTELLiSTEM Technologies is a privately-owned biotechnology company engineering the next generation cell therapy products using stem cells. Its proprietary genetically engineered cell platforms include Super Sentinel Cells™ (SSCs) for cancer therapeutics and IntelliCells™ for drug discovery and target identification. INTELLiSTEM is currently moving into human clinical trials.

2.4 / 5 ( 41 votes )

Filed Under: Coronavirus (COVID-19) Tagged With: Coronavirus

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Comments

  1. Corazon Patos says

    April 7, 2020 at 9:54 pm

    Congratulations Dr. Riam.
    You are amazing.
    We pray and hope for the success of your project.
    This is great; will benefit the whole world.
    We are so proud and very happy for you.
    God bless.

  2. ROBERT P says

    April 8, 2020 at 1:19 pm

    Very insightful and looks quite promising. Hopefully this is the key to unlocking an effective antidote.

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Stem cell conferences

The Complete Guide To Virtual Stem Cell Conferences in 2021

CO.DON AG

The New CO.DON Plant for the EU-approved Advanced Therapy Cartilage Regeneration Treatment Sets a Milestone in Cell Therapy for Commercial Manufacturing

Safety Chart | The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy

The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.